Jubilant Pharmova Ltd.

Financial

	Jubilant Pharmova	Sanofi India	Caplin Point Lab
Operational Metrics
API Sector
Australia DMF fillings	14.0 .	n/a	n/a
US DMF Filings	98.0 .	n/a	n/a
Canada DMF fillings	42.0 .	n/a	n/a
Japan DMF Filings	15.0 .	n/a	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	100.0 .	n/a	46.0 .
Number of ANDA's Approved By USFDA	62.0 .	n/a	33.0 .
Number of ANDA's Filed in Europe	38.0	n/a	n/a
Number of ANDA's Approved in Europe	37.0	n/a	n/a
Number of ANDA's Filed in Canada	24.0	n/a	n/a
Number of ANDA's Approved by Canada	24.0	n/a	n/a
R&D as a % of Total Sales	0.33 %	0.0	4.4 %
Financials
5 yr Average ROE	8.35 %	43.25 %	20.61 %
5yr average Equity Multiplier	2.0	3.33	1.17
5yr Average Asset Turnover Ratio	0.59	0.52	0.72
5yr Avg Net Profit Margin	7.13 %	25.25 %	24.8 %
Price to Book	2.48	17.22	5.64
P/E	23.47	35.86	27.85
5yr Avg Cash Conversion Cycle	-19.21 Days	24.48 Days	79.85 Days
Inventory Days	81.78 Days	66.8 Days	64.55 Days
Days Receivable	51.11 Days	31.98 Days	100.92 Days
Days Payable	173.51 Days	63.37 Days	74.04 Days
5yr Average Interest Coverage Ratio	3.98	906.11	579.71
5yr Avg ROCE	9.05 %	25.91 %	25.27 %
5yr Avg Operating Profit Margin	18.69 %	25.97 %	30.87 %
5 yr average Debt to Equity	0.64	0.0	0.01
5yr CAGR Net Profit	-38.8 %	31.63 %	16.28 %
5yr Average Return on Assets	4.23 %	13.01 %	17.7 %
Shareholdings
Promoter Holding	50.68 %	60.4 %	70.56 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	0.0	1.67 %
Change in Mutual Fund Holding (3 Yrs)	3.61 %	1.07 %	0.55 %

Business

	Jubilant Pharmova	Sanofi India	Caplin Point Lab
Product Wise Break-Up	Product Wise Break-Up Radiopharmaceuticals 44.9 Contract Manufacturing 16.81 Solid dosage formulations 10.82 Anti-allergic 10.21 Active Pharmaceutical Ingredient (API) 9.26 Contract Research and Development Services 6.7 India branded pharmaceuticals 0.72 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 Pharmaceuticals 0 Branded Generic 0 Generic 0 Others 0.58	Product Wise Break-Up 0 Nutritional products 0 Anti-allergic 0 India branded pharmaceuticals 0 Pharmaceutical 100.0 Branded Generic 0 Contract Manufacturing 0 Solid dosage formulations 0 Life science chemicals 0 Generic 0 Specialty intermediates 0 Radiopharmaceuticals 0 Active Pharmaceutical Ingredient (API) 0	Product Wise Break-Up 0 Nutritional products 0 Anti-allergic 0 India branded pharmaceuticals 0 Pharmaceuticals 0 Branded Generics 25.0 Contract Manufacturing 0 Solid dosage formulations 0 Life science chemicals 0 Formulations 75.0 Specialty intermediates 0 Radiopharmaceuticals 0 Active Pharmaceutical Ingredient (API) 0
Segment Break-Up	Segment Break-Up Radiopharma 45.97 CDMO Sterile Injectables 17.28 Drug discovery and development solutions 16.33 Generics 10.91 Allergy Immunotherapy 9.51 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0	-	-
Location Wise Break-Up	Location Wise Break-Up Americas and Europe 90.17 Rest of the World 7.5 India 2.33 China 0 Singapore 0 USA 0 Africa 0 LATAM 0	Location Wise Break-Up Rest of the World 0 India 81.47 USA 0 Americas and Europe 0 LATAM 0 China 0 Singapore 17.88 Africa 0 Others 0.65	Location Wise Break-Up Rest of the World 0 India 0 USA 18.0 Americas and Europe 0 Latin America 80.0 China 0 Singapore 0 Africa 2.0
Operating Profit Break-Up	Operating Profit Break-Up Radiopharma 41.47 Allergy Immunotherapy 20.39 Contract Research and Development 15.39 CDMO Sterile Injectables 14.56 Generics 8.2 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0	-	-
Capex	Capex CDMO 58.69 Radiopharma 20.6 Contract Research and Development 15.56 Generics 2.12 Allergy Immunotherapy 1.54 Proprietary Novel Drugs 1.49 Life Science Ingredients 0	-	-
Asset Break-Up	Asset Break-Up Contract Research and Development 12.96 Proprietary Novel Drugs 2.16 Life Science Ingredients 0 Pharmaceuticals 0 Others 84.88	-	-

Jubilant Pharmova Ltd.

SIGN UP FOR FREE